Highest-materiality recent filing
Lifeward acquired Oramed's wholly-owned subsidiary Oratech for 1,250,363 ordinary shares, 1,006,113 pre-funded warrants, and share purchase warrants.
Oramed deferred its right to receive an amortization payment from Scilex due Oct 1, 2025; payment was made in Nov 2025.
Oramed to receive up to 49.9% beneficial ownership in Lifeward via shares, pre-funded warrants, plus 4% revenue sharing on ReWalk net sales (max 10 years).
Oramed receives $18M payment from Scilex, approves $0.25/share dividend
$18M payment from Scilex closes Option Agreement; current returns total $118M on $99.5M investment.
Oramed reports nine-month 2025 net income of $65M, up from loss of $6.1M
Net income (pre-tax) of $65.0M vs. $6.1M loss; basic EPS $1.30, diluted $1.26.
Repurchased 1,155,367 shares from HTIT Biotech at $2.23/share for $2.58M total; shares cancelled.
Oramed grants Scilex option to repurchase Penny Warrants for up to $27M; clarifies warrant terms
Scilex pays $1.5M option fee in two installments ($750K by Aug 8, 2025; $750K by Dec 16, 2025).
Oramed invests $36.9M in Alpha Tau, acquires 14.1M shares at $2.612/share
Oramed subsidiary purchased ~14.1M shares of Alpha Tau (NASDAQ: DRTS) for $36.9M ($2.612/share) via registered direct offering.
RoyaltyVest (50% owned by Oramed) obtains exclusive license to develop, manufacture and commercialize ZTlido (lidocaine 1.8%) and SP-103 outside the U.S.
Oramed spins off oral insulin into OraTech JV with HTIT; $75M total investment, Nasdaq IPO planned
HTIT to invest $60M, Oramed $15M into OraTech; Oramed shareholders to receive direct stake in new Nasdaq-listed company.
Oramed extends Scilex note maturity to Dec 2025; receives 3.25M Scilex shares as consideration
Remaining principal on Tranche A Note is $7.675M; maturity extended from March 21, 2025 to December 31, 2025.
Oramed defers Scilex $6.25M amortization; receives 2.5M free-trading Scilex shares
Initial $6.25M amortization due Jan 2, 2025 deferred to Jan 31; further deferral to Oct 2026 conditional on royalty grant.
Oramed recieves $13.2M from Scilex, slashing Tranche A principal to $7.7M
Scilex paid ~$13.2M on Dec 13, 2024, satisfying the $15M installment due Dec 21.
Oramed restructures Scilex debt: exchanges $25M note for convertible notes, warrants, and royalty
Oramed exchanged $22.5M of its Scilex note for a $25M 5.5% convertible note due 2026 and 3.75M warrants at $1.09.
Oramed signs $11.5M CRO agreement for Phase 3 trial of ORMD-0801 in type 2 diabetes
Oramed Ltd. subsidiary retained InClin as CRO for planned Phase 3 trial of oral insulin candidate ORMD-0801.
Oramed & Scilex amend note: $2M prepayment, warrant exercise, liquidity waiver
Scilex pays Oramed $2M Sept 23: $1.7M to March 2025 amort, $300K buys back 4M $11.50 warrants.
Oramed CFO David Silberman resigns, effective July 12, 2024
David Silberman stepped down as CFO, Treasurer and Secretary for personal reasons.
On June 6, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Avraham Gabay to serve as the Chief Financial Officer, Treasurer and Secretary of the Company, effective as of June 18, 2024.
On May 10, 2024, David Silberman, the Chief Financial Officer, Treasurer and Secretary (the “CFO”) of Oramed Pharmaceuticals Inc. (the “Company”), resigned from his positions with the Company for personal reasons, effective as of July 12, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material